Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics is a Duke start-up and DCP portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).
Invented at Duke 2023 showcases a bustling innovation ecosystem
Featuring inventor booths, innovation resources, and strong support in speeches from leaders, Invented at Duke 2023 caps a big year for OTC.
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
This application of vorasidenib is based on licensed technology developed by Dr. Darell Bigner (Neurobiology, SOM) and colleagues.
Gilhuly Accelerator Fund Invests Over $1M in Duke Inventor Projects in its Inaugural Year
The Duke community, led by Trustee Ned Gilhuly, is supporting Duke inventors with its newest translational fund dedicated to accelerating the development of early-stage technologies with high commercial potential.
NCBiotech Awards $2.75 Million in Grants, Loans in Latest Quarter
Two Duke start-ups received loans & four Duke projects received Translational Research Grants. Recipients hail from across the university!
Synthetic Antibiotic Could Be Effective Against Drug-Resistant Superbugs
Decades of work by a series of Duke investigators yields new drug, patents and a startup company Valanbio Therapeutics
Newly Identified Lipid in Breast Milk Might Reduce Cerebral Palsy in Infants
Tellus Therapeutics, a neonatal white matter injury therapeutics start-up, was co-founded by Dr. Eric Brenner (Pediatrics, SOM)
First-time faculty gift to Duke Science and Technology to support university’s translation and commercialization efforts
$1M gift from IonQ co-founder Professor Jungsang Kim (ECE, Pratt) and Soyeon Nam helps OTC accelerate commercialization of Duke inventions
Tune Therapeutics Unveils Breakthrough Data Showing Stable and Durable Epigenetic Regulation in Non-Human Primates
Tune Therapeutics is a Duke University start-up developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).